{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:27:56Z","timestamp":1790818076034,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,22]],"date-time":"2021-06-22T00:00:00Z","timestamp":1624320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["102398"],"award-info":[{"award-number":["102398"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012658","name":"National Council for Eurasian and East European Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012658","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C99667\/A12918"],"award-info":[{"award-number":["C99667\/A12918"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2012-StG-311460 DrugE3CRLs"],"award-info":[{"award-number":["ERC-2012-StG-311460 DrugE3CRLs"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jbc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biological Chemistry"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jbc.2021.100910","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T08:16:52Z","timestamp":1624522612000},"page":"100910","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Von Hippel\u2013Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein"],"prefix":"10.1016","volume":"297","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8209-2575","authenticated-orcid":false,"given":"Julianty","family":"Frost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2413-4981","authenticated-orcid":false,"given":"Sonia","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8654-1670","authenticated-orcid":false,"given":"Alessio","family":"Ciulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbc.2021.100910_bib1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1126\/science.284.5414.657","article-title":"Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase","volume":"284","author":"Kamura","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jbc.2021.100910_bib2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.str.2017.04.009","article-title":"Crystal structure of the Cul2-Rbx1-EloBC-VHL ubiquitin ligase complex","volume":"25","author":"Cardote","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.jbc.2021.100910_bib3","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jbc.2021.100910_bib4","doi-asserted-by":"crossref","first-page":"20","DOI":"10.15586\/jkcvhl.2017.88","article-title":"A\u00a0review of von Hippel-Lindau syndrome","volume":"4","author":"Varshney","year":"2017","journal-title":"J.\u00a0Kidney Cancer VHL"},{"key":"10.1016\/j.jbc.2021.100910_bib5","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/annonc\/mdw241","article-title":"Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: Putting it together with a translational perspective","volume":"27","author":"Shenoy","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jbc.2021.100910_bib6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/00005792-199711000-00001","article-title":"von Hippel-Lindau disease","volume":"76","author":"Maher","year":"1997","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jbc.2021.100910_bib7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/biomedicines6010035","article-title":"VHL and hypoxia signaling: Beyond HIF in cancer","volume":"6","author":"Zhang","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.jbc.2021.100910_bib8","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1038\/onc.2016.495","article-title":"Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL","volume":"36","author":"Hasanov","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2021.100910_bib9","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.aap8411","article-title":"VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma","volume":"361","author":"Zhang","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.jbc.2021.100910_bib10","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cell.2015.03.011","article-title":"A\u00a0lactate-induced response to hypoxia","volume":"161","author":"Lee","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.jbc.2021.100910_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016975","article-title":"Quantitative proteomics identifies the Myb-binding protein p160 as a novel target of the von Hippel-Lindau tumor suppressor","volume":"6","author":"Lai","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jbc.2021.100910_bib12","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1038\/onc.2011.442","article-title":"Complex cellular functions of the von Hippel-Lindau tumor suppressor gene: Insights from model organisms","volume":"31","author":"Hsu","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.jbc.2021.100910_bib13","doi-asserted-by":"crossref","first-page":"13312","DOI":"10.1038\/ncomms13312","article-title":"Potent and selective chemical probe of hypoxic signalling downstream of HIF-alpha hydroxylation via VHL inhibition","volume":"7","author":"Frost","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2021.100910_bib14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1021\/acs.jmedchem.7b00675","volume":"61","author":"Soares","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2021.100910_bib15","doi-asserted-by":"crossref","first-page":"8657","DOI":"10.1021\/jm5011258","article-title":"Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von Hippel-Lindau (VHL) E3 ubiquitin ligase and the hypoxia inducible factor (HIF) alpha subunit with in\u00a0vitro nanomolar affinities","volume":"57","author":"Galdeano","year":"2014","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.jbc.2021.100910_bib16","doi-asserted-by":"crossref","first-page":"17","DOI":"10.12688\/wellcomeopenres.15044.1","article-title":"RNA-seq analysis of PHD and VHL inhibitors reveals differences and similarities to the hypoxia response","volume":"4","author":"Frost","year":"2019","journal-title":"Wellcome Open Res."},{"key":"10.1016\/j.jbc.2021.100910_bib17","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.bbrc.2018.09.172","article-title":"von Hippel-Lindau (VHL) protein antagonist, VH298, promotes functional activities of tendon-derived stem cells and accelerates healing of entheses in rats by inhibiting ubiquitination of hydroxy-HIF-1alpha","volume":"505","author":"Qiu","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jbc.2021.100910_bib18","first-page":"1897174","article-title":"von Hippel-Lindau (VHL) protein antagonist VH298 improves wound healing in streptozotocin-induced hyperglycaemic rats by activating hypoxia-inducible factor- (HIF-) 1 signalling","volume":"2019","author":"Qiu","year":"2019","journal-title":"J.\u00a0Diabetes Res."},{"key":"10.1016\/j.jbc.2021.100910_bib19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ddtec.2019.01.002","article-title":"PROteolysis TArgeting Chimeras (PROTACs) - past, present and future","volume":"31","author":"Pettersson","year":"2019","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.jbc.2021.100910_bib20","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.cbpa.2019.07.003","article-title":"Bifunctional chemical probes inducing protein-protein interactions","volume":"52","author":"Maniaci","year":"2019","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.jbc.2021.100910_bib21","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.molcel.2020.01.010","article-title":"Harnessing the power of proteolysis for targeted protein inactivation","volume":"77","author":"Verma","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jbc.2021.100910_bib22","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1021\/acschembio.5b00216","article-title":"Selective small molecule induced degradation of the BET bromodomain protein BRD4","volume":"10","author":"Zengerle","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jbc.2021.100910_bib23","doi-asserted-by":"crossref","first-page":"7124","DOI":"10.1073\/pnas.1521738113","article-title":"PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer","volume":"113","author":"Raina","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U.\u00a0S. A."},{"key":"10.1016\/j.jbc.2021.100910_bib24","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jbc.2021.100910_bib25","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nchembio.1858","article-title":"Catalytic in\u00a0vivo protein knockdown by small-molecule PROTACs","volume":"11","author":"Bondeson","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.jbc.2021.100910_bib26","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A\u00a0chemoproteomic approach to query the degradable kinome using a multi-kinase degrader","volume":"25","author":"Huang","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.jbc.2021.100910_bib27","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1021\/acschembio.9b00505","article-title":"Design and characterization of SGK3-PROTAC1, an isoform specific SGK3 kinase PROTAC degrader","volume":"14","author":"Tovell","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jbc.2021.100910_bib28","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41467-017-00954-1","article-title":"Homo-PROTACs: Bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation","volume":"8","author":"Maniaci","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jbc.2021.100910_bib29","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1021\/pr101060v","article-title":"More than 100,000 detectable peptide species elute in single shotgun proteomics runs but the majority is inaccessible to data-dependent LC-MS\/MS","volume":"10","author":"Michalski","year":"2011","journal-title":"J.\u00a0Proteome Res."},{"key":"10.1016\/j.jbc.2021.100910_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/biomedicines6020047","article-title":"Hypoxia and chromatin: A focus on transcriptional repression mechanisms","volume":"6","author":"Batie","year":"2018","journal-title":"Biomedicines"},{"key":"10.1016\/j.jbc.2021.100910_bib31","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jplph.2013.11.009","article-title":"The dormancy-breaking stimuli \u201cchilling, hypoxia and cyanamide exposure\u201d up-regulate the expression of alpha-amylase genes in grapevine buds","volume":"171","author":"Rubio","year":"2014","journal-title":"J.\u00a0Plant Physiol."},{"key":"10.1016\/j.jbc.2021.100910_bib32","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm0895-822","article-title":"Tumour suppression by the human von Hippel-Lindau gene product","volume":"1","author":"Iliopoulos","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbc.2021.100910_bib33","doi-asserted-by":"crossref","first-page":"11661","DOI":"10.1073\/pnas.95.20.11661","article-title":"pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation","volume":"95","author":"Iliopoulos","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2021.100910_bib34","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.1073\/pnas.95.15.8817","article-title":"A\u00a0second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor","volume":"95","author":"Schoenfeld","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2021.100910_bib35","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1042\/BJ20081055","article-title":"Regulation of gene expression by hypoxia","volume":"414","author":"Kenneth","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.jbc.2021.100910_bib36","doi-asserted-by":"crossref","first-page":"10210","DOI":"10.1038\/srep10210","article-title":"K63 linked ubiquitin chain formation is a signal for HIF1A degradation by Chaperone-Mediated Autophagy","volume":"5","author":"Ferreira","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jbc.2021.100910_bib37","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1389202911314020003","article-title":"Integrated analysis of transcriptomic and proteomic data","volume":"14","author":"Haider","year":"2013","journal-title":"Curr. Genomics"},{"key":"10.1016\/j.jbc.2021.100910_bib38","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.biocel.2011.08.003","article-title":"The emerging role of nuclear factor kappa B in renal cell carcinoma","volume":"43","author":"Morais","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.jbc.2021.100910_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2016.09.009","article-title":"pVHL mediates K63-linked ubiquitination of IKKbeta, leading to IKKbeta inactivation","volume":"383","author":"Wang","year":"2016","journal-title":"Cancer Lett."},{"key":"10.1016\/j.jbc.2021.100910_bib40","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1083\/jcb.201608024","article-title":"VHL promotes immune response against renal cell carcinoma via NF-kappaB-dependent regulation of VCAM-1","volume":"216","author":"Labrousse-Arias","year":"2017","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.jbc.2021.100910_bib41","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.chembiol.2012.08.015","article-title":"Dissecting fragment-based lead discovery at the von Hippel-Lindau protein:hypoxia inducible factor 1alpha protein-protein interface","volume":"19","author":"Van Molle","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.jbc.2021.100910_bib42","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1073\/pnas.0705680105","article-title":"PHDs overactivation during chronic hypoxia \u201cdesensitizes\u201d HIFalpha and protects cells from necrosis","volume":"105","author":"Ginouves","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2021.100910_bib43","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/MNH.0000000000000431","article-title":"Hypoxia-inducible factor stabilizers for treating anemia of chronic kidney disease","volume":"27","author":"Hasegawa","year":"2018","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"10.1016\/j.jbc.2021.100910_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1126\/science.aad9642","article-title":"Hypoxia as a therapy for mitochondrial disease","volume":"352","author":"Jain","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jbc.2021.100910_bib45","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1016\/j.bmc.2019.02.048","article-title":"Cereblon versus VHL: Hijacking E3 ligases against each other using PROTACs","volume":"27","author":"Girardini","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jbc.2021.100910_bib46","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A\u00a0selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.jbc.2021.100910_bib47","doi-asserted-by":"crossref","first-page":"12544","DOI":"10.1074\/jbc.274.18.12544","article-title":"Ligand-mediated induction of thymidylate synthase occurs by enzyme stabilization. Implications for autoregulation of translation","volume":"274","author":"Kitchens","year":"1999","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.jbc.2021.100910_bib48","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1073\/pnas.1018001108","article-title":"Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors","volume":"109","author":"Chakrabarty","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbc.2021.100910_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000925","article-title":"Drug-induced regulation of target expression","volume":"6","author":"Iskar","year":"2010","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.jbc.2021.100910_bib50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/02841869109091819","article-title":"Genetic mechanisms of drug resistance. A review","volume":"30","author":"Borst","year":"1991","journal-title":"Acta Oncol."},{"key":"10.1016\/j.jbc.2021.100910_bib51","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1073\/pnas.062036899","article-title":"Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: A method to modulate gene expression","volume":"99","author":"Mayer-Kuckuk","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Journal of Biological Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925821007109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021925821007109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:31:52Z","timestamp":1762187512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021925821007109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0021925821007109"],"URL":"https:\/\/doi.org\/10.1016\/j.jbc.2021.100910","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.04.12.439487","asserted-by":"object"}],"has-review":[{"id-type":"doi","id":"10.3410\/f.740371820.793590433","asserted-by":"object"}]},"ISSN":["0021-9258"],"issn-type":[{"value":"0021-9258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Von Hippel\u2013Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein","name":"articletitle","label":"Article Title"},{"value":"Journal of Biological Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbc.2021.100910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc on behalf of American Society for Biochemistry and Molecular Biology.","name":"copyright","label":"Copyright"}],"article-number":"100910"}}